Search

Your search keyword '"Fridman, Wolf Hervé"' showing total 171 results
Start Over Author "Fridman, Wolf Hervé"
171 results on '"Fridman, Wolf Hervé"'

1. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas

Author

Lu, Xiaofan, Vano, Yann-Alexandre, Su, Xiaoping, Helleux, Alexandra, Lindner, Véronique, Mouawad, Roger, Spano, Jean-Philippe, Rouprêt, Morgan, Compérat, Eva, Verkarre, Virginie, Sun, Cheng-Ming, Bennamoun, Mostefa, Lang, Hervé, Barthelemy, Philippe, Cheng, Wenxuan, Xu, Li, Davidson, Irwin, Yan, Fangrong, Fridman, Wolf Hervé, Sautes-Fridman, Catherine, Oudard, Stéphane, and Malouf, Gabriel G.

Published
2023
Full Text
View/download PDF

2. Consensus nomenclature for CD8+ T cell phenotypes in cancer

Author

Apetoh, Lionel, Smyth, Mark J, Drake, Charles G, Abastado, Jean-Pierre, Apte, Ron N, Ayyoub, Maha, Blay, Jean-Yves, Bonneville, Marc, Butterfield, Lisa H, Caignard, Anne, Castelli, Chiara, Cavallo, Federica, Celis, Esteban, Chen, Lieping, Colombo, Mario P, Comin-Anduix, Begoña, Coukos, Georges, Dhodapkar, Madhav V, Dranoff, Glenn, Frazer, Ian H, Fridman, Wolf-Hervé, Gabrilovich, Dmitry I, Gilboa, Eli, Gnjatic, Sacha, Jäger, Dirk, Kalinski, Pawel, Kaufman, Howard L, Kiessling, Rolf, Kirkwood, John, Knuth, Alexander, Liblau, Roland, Lotze, Michael T, Lugli, Enrico, Marincola, Francesco, Melero, Ignacio, Melief, Cornelis J, Mempel, Thorsten R, Mittendorf, Elizabeth A, Odun, Kunle, Overwijk, Willem W, Palucka, Anna Karolina, Parmiani, Giorgio, Ribas, Antoni, Romero, Pedro, Schreiber, Robert D, Schuler, Gerold, Srivastava, Pramod K, Tartour, Eric, Valmori, Danila, van der Burg, Sjoerd H, van der Bruggen, Pierre, van den Eynde, Benoît J, Wang, Ena, Zou, Weiping, Whiteside, Theresa L, Speiser, Daniel E, Pardoll, Drew M, Restifo, Nicholas P, and Anderson, Ana C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, 2.1 Biological and endogenous factors, Aetiology, anergy, anticancer immunity, CD8(+) T cells, cytotoxicity, exhaustion, effector, IFN gamma, senescence, stemness, CD8+ T cells, IFNγ, Oncology and carcinogenesis
Abstract

Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.

Published
2015

3. Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors

Author

Verbiest, Annelies, Renders, Inne, Caruso, Stefano, Couchy, Gabrielle, Job, Sylvie, Laenen, Annouschka, Verkarre, Virginie, Rioux-Leclercq, Nathalie, Schöffski, Patrick, Vano, Yann, Elaidi, Reza-Thierry, Lerut, Evelyne, Albersen, Maarten, Oudard, Stéphane, Fridman, Wolf-Hervé, Sautès-Fridman, Catherine, Albigès, Laurence, Wozniak, Agnieszka, Zucman-Rossi, Jessica, and Beuselinck, Benoit

Published
2019
Full Text
View/download PDF

7. Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.

Author

Vano, Yann-Alexandre, primary, Phan, Letuan, additional, Simonaggio, Audrey, additional, Bennamoun, Mostefa, additional, Pannier, Diane, additional, Chevreau, Christine, additional, Borchiellini, Delphine, additional, Maillet, Denis, additional, Gross-Goupil, Marine, additional, Laguerre, Brigitte, additional, Tournigand, Christophe, additional, Barthelemy, Philippe, additional, Coquan, Elodie, additional, Gravis, Gwenaelle, additional, Sun, Cheng-Ming, additional, Meylan, Maxime, additional, Fridman, Wolf-Hervé, additional, Sautès-Fridman, Catherine, additional, Elaidi, Réza, additional, and Oudard, Stephane, additional

Published
2023
Full Text
View/download PDF

11. Identifying gut microbial signatures associated with B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB).

Author

Nassif, Elise F, primary, Chelvanambi, Manoj, additional, Chen, Lili, additional, Wu, Chia-Chin, additional, Damania, Ashish, additional, Keung, Emily Zhi-Yun, additional, Witt, Russell G., additional, White, Michael, additional, Ajami, Nadim J., additional, Wong, Matthew C., additional, Somaiah, Neeta, additional, Sepesi, Boris, additional, Basu, Sreyashi, additional, Allison, James Patrick, additional, Sharma, Padmanee, additional, McBride, Kevin, additional, Fridman, Wolf-Hervé, additional, Wargo, Jennifer Ann, additional, Cascone, Tina, additional, and Roland, Christina Lynn, additional

Published
2022
Full Text
View/download PDF

16. De la traversée du désert au prix Nobel de Physiologie ou Médecine décerné à James Allison et Tasuku Honjo : la longue marche de l’immunothérapie des cancers: Entretien avec Wolf Hervé Fridman

Author

Fridman, Wolf Hervé, Teillaud, Jean-Luc, Sciences, EDP, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Centre d'Immunologie et des Maladies Infectieuses (CIMI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; No abstract available

Published
2019

18. Trial watch

Author

Senovilla, Laura, Vacchelli, Erika, Galon, Jerome, Adjemian, Sandy, Eggermont, Alexander, Fridman, Wolf Hervé, Sautès-Fridman, Catherine, Ma, Yuting, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, and Galluzzi, Lorenzo

Subjects
transforming growth factor, interferon γ, plasmacytoid dendritic cells, interleukin-10, biomarker, chemical and pharmacologic phenomena, Review, chemotherapy, cytokines
Abstract

Solid tumors are constituted of a variety of cellular components, including bona fide malignant cells as well as endothelial, structural and immune cells. On one hand, the tumor stroma exerts major pro-tumorigenic and immunosuppressive functions, reflecting the capacity of cancer cells to shape the microenvironment to satisfy their own metabolic and immunological needs. On the other hand, there is a component of tumor-infiltrating leucocytes (TILs) that has been specifically recruited in the attempt to control tumor growth. Along with the recognition of the critical role played by the immune system in oncogenesis, tumor progression and response to therapy, increasing attention has been attracted by the potential prognostic and/or predictive role of the immune infiltrate in this setting. Data from large clinical studies demonstrate indeed that a robust infiltration of neoplastic lesions by specific immune cell populations, including (but not limited to) CD8(+) cytotoxic T lymphocytes, Th1 and Th17 CD4(+) T cells, natural killer cells, dendritic cells, and M1 macrophages constitutes an independent prognostic indicator in several types of cancer. Conversely, high levels of intratumoral CD4(+)CD25(+)FOXP3(+) regulatory T cells, Th2 CD4(+) T cells, myeloid-derived suppressor cells, M2 macrophages and neutrophils have frequently been associated with dismal prognosis. So far, only a few studies have addressed the true predictive potential of TILs in cancer patients, generally comforting the notion that-at least in some clinical settings-the immune infiltrate can reliably predict if a specific patient will respond to therapy or not. In this Trial Watch, we will summarize the results of clinical trials that have evaluated/are evaluating the prognostic and predictive value of the immune infiltrate in the context of solid malignancies.

Published
2012

21. Trial Watch: Immunotherapy plus radiation therapy for oncological indications

Author

Vacchelli, Erika, primary, Bloy, Norma, additional, Aranda, Fernando, additional, Buqué, Aitziber, additional, Cremer, Isabelle, additional, Demaria, Sandra, additional, Eggermont, Alexander, additional, Formenti, Silvia Chiara, additional, Fridman, Wolf Hervé, additional, Fucikova, Jitka, additional, Galon, Jérôme, additional, Spisek, Radek, additional, Tartour, Eric, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2016
Full Text
View/download PDF

22. Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

Author

Buqué, Aitziber, primary, Bloy, Norma, additional, Aranda, Fernando, additional, Cremer, Isabelle, additional, Eggermont, Alexander, additional, Fridman, Wolf Hervé, additional, Fucikova, Jitka, additional, Galon, Jérôme, additional, Spisek, Radek, additional, Tartour, Eric, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2016
Full Text
View/download PDF

24. Trial Watch—Immunostimulation with cytokines in cancer therapy

Author

Vacchelli, Erika, primary, Aranda, Fernando, additional, Bloy, Norma, additional, Buqué, Aitziber, additional, Cremer, Isabelle, additional, Eggermont, Alexander, additional, Fridman, Wolf Hervé, additional, Fucikova, Jitka, additional, Galon, Jérôme, additional, Spisek, Radek, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2015
Full Text
View/download PDF

25. Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Author

Iribarren, Kristina, primary, Bloy, Norma, additional, Buqué, Aitziber, additional, Cremer, Isabelle, additional, Eggermont, Alexander, additional, Fridman, Wolf Hervé, additional, Fucikova, Jitka, additional, Galon, Jérôme, additional, Špíšek, Radek, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2015
Full Text
View/download PDF

27. Trial Watch: Adoptive cell transfer for oncological indications

Author

Aranda, Fernando, primary, Buqué, Aitziber, additional, Bloy, Norma, additional, Castoldi, Francesca, additional, Eggermont, Alexander, additional, Cremer, Isabelle, additional, Fridman, Wolf Hervé, additional, Fucikova, Jitka, additional, Galon, Jérôme, additional, Spisek, Radek, additional, Tartour, Eric, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2015
Full Text
View/download PDF

28. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Author

Buqué, Aitziber, primary, Bloy, Norma, additional, Aranda, Fernando, additional, Castoldi, Francesca, additional, Eggermont, Alexander, additional, Cremer, Isabelle, additional, Fridman, Wolf Hervé, additional, Fucikova, Jitka, additional, Galon, Jérôme, additional, Marabelle, Aurélien, additional, Spisek, Radek, additional, Tartour, Eric, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2015
Full Text
View/download PDF

29. Consensus nomenclature for CD8+T cell phenotypes in cancer

Author

Apetoh, Lionel, primary, Smyth, Mark J., additional, Drake, Charles G., additional, Abastado, Jean-Pierre, additional, Apte, Ron N., additional, Ayyoub, Maha, additional, Blay, Jean-Yves, additional, Bonneville, Marc, additional, Butterfield, Lisa H., additional, Caignard, Anne, additional, Castelli, Chiara, additional, Cavallo, Federica, additional, Celis, Esteban, additional, Chen, Lieping, additional, Colombo, Mario P., additional, Comin-Anduix, Begoña, additional, Coukos, Georges, additional, Dhodapkar, Madhav V., additional, Dranoff, Glenn, additional, Frazer, Ian H., additional, Fridman, Wolf-Hervé, additional, Gabrilovich, Dmitry I., additional, Gilboa, Eli, additional, Gnjatic, Sacha, additional, Jäger, Dirk, additional, Kalinski, Pawel, additional, Kaufman, Howard L., additional, Kiessling, Rolf, additional, Kirkwood, John, additional, Knuth, Alexander, additional, Liblau, Roland, additional, Lotze, Michael T., additional, Lugli, Enrico, additional, Marincola, Francesco, additional, Melero, Ignacio, additional, Melief, Cornelis J., additional, Mempel, Thorsten R., additional, Mittendorf, Elizabeth A., additional, Odun, Kunle, additional, Overwijk, Willem W., additional, Palucka, Anna Karolina, additional, Parmiani, Giorgio, additional, Ribas, Antoni, additional, Romero, Pedro, additional, Schreiber, Robert D., additional, Schuler, Gerold, additional, Srivastava, Pramod K., additional, Tartour, Eric, additional, Valmori, Danila, additional, van der Burg, Sjoerd H., additional, van der Bruggen, Pierre, additional, van den Eynde, Benoît J., additional, Wang, Ena, additional, Zou, Weiping, additional, Whiteside, Theresa L., additional, Speiser, Daniel E., additional, Pardoll, Drew M., additional, Restifo, Nicholas P., additional, and Anderson, Ana C., additional

Published
2015
Full Text
View/download PDF

30. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

Author

Vacchelli, Erika, primary, Pol, Jonathan, additional, Bloy, Norma, additional, Eggermont, Alexander, additional, Cremer, Isabelle, additional, Fridman, Wolf Hervé, additional, Galon, Jérôme, additional, Marabelle, Aurélien, additional, Kohrt, Holbrook, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2015
Full Text
View/download PDF

31. Trial watch: Dendritic cell-based anticancer therapy

Author

Bloy, Norma, primary, Pol, Jonathan, additional, Aranda, Fernando, additional, Eggermont, Alexander, additional, Cremer, Isabelle, additional, Fridman, Wolf Hervé, additional, Fučíková, Jitka, additional, Galon, Jérôme, additional, Tartour, Eric, additional, Spisek, Radek, additional, Dhodapkar, Madhav V., additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2014
Full Text
View/download PDF

32. Trial Watch

Author

Aranda, Fernando, primary, Vacchelli, Erika, additional, Eggermont, Alexander, additional, Galon, Jérôme, additional, Fridman, Wolf Hervé, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2014
Full Text
View/download PDF

33. The European Academy of Tumor Immunology

Author

Kroemer, Guido, Fridman, Wolf Hervé, Sautès-Fridman, Catherine, and Zitvogel, Laurence

Subjects
Editor's Corner
Abstract

THE EUROPEAN ACADEMY OF TUMOR IMMUNOLOGY (EATI, OFFICIAL WEBSITE: http://eati.landesbioscience.com/index.html) has been founded in 2011 with the idea of creating a novel organization that responds to the need of structuring the European research space in this expanding, clinically ever more important area of research. Rapidly, this initiative, which regroups (part of) the elite of tumor immunologists, has been joined by 110 scientists, who accepted to join EATI as founding members. Obviously, EATI will not enter in competition with existing prestigious organizations, be they supranational (such as the Cancer Research Institute, CRI; the European Society for Cancer Immunology and Immunotherapy, ESCII; and the Society for the Immunotherapy of Cancer, SITC), or national [such as the Cancer Immunology Working Group, CIMM, of the American Association for Cancer Reserch; the (German) Association for Cancer Immunotherapy, CIMT; the (US) Cancer Immunotherapy Consortium, CIC; the (US) Cancer Vaccine Consortium, CVC; and the Italian Network for Cancer Biotherapy, NIBIT]. The choice of cooperation (rather than competition) with these organizations is clearly documented by the fact that many prominent members of CIMM, CIC, CIMT, CRI, CVC, ESCII, NIBIT and SITC are also EATI Academicians.

Published
2012

34. Trial watch

Author

Vacchelli, Erika, primary, Vitale, Ilio, additional, Eggermont, Alexander, additional, Fridman, Wolf Hervé, additional, Fučíková, Jitka, additional, Cremer, Isabelle, additional, Galon, Jérôme, additional, Tartour, Eric, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2013
Full Text
View/download PDF

35. Trial watch

Author

Senovilla, Laura, primary, Vacchelli, Erika, additional, Garcia, Pauline, additional, Eggermont, Alexander, additional, Fridman, Wolf Hervé, additional, Galon, Jérôme, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2013
Full Text
View/download PDF

37. Trial watch

Author

Vacchelli, Erika, primary, Martins, Isabelle, additional, Eggermont, Alexander, additional, Fridman, Wolf Hervé, additional, Galon, Jerome, additional, Sautès-Fridman, Catherine, additional, Tartour, Eric, additional, Zitvogel, Laurence, additional, Kroemer, Guido, additional, and Galluzzi, Lorenzo, additional

Published
2012
Full Text
View/download PDF

38. Trial watch

Author

Galluzzi, Lorenzo, primary, Senovilla, Laura, additional, Vacchelli, Erika, additional, Eggermont, Alexander, additional, Fridman, Wolf Hervé, additional, Galon, Jérôme, additional, Sautès-Fridman, Catherine, additional, Tartour, Eric, additional, Zitvogel, Laurence, additional, and Kroemer, Guido, additional

Published
2012
Full Text
View/download PDF

40. Trial Watch: Monoclonal antibodies in cancer therapy

Author

Galluzzi, Lorenzo, primary, Vacchelli, Erika, additional, Fridman, Wolf Hervé, additional, Galon, Jerome, additional, Sautès-Fridman, Catherine, additional, Tartour, Eric, additional, Zucman-Rossi, Jessica, additional, Zitvogel, Laurence, additional, and Kroemer, Guido, additional

Published
2012
Full Text
View/download PDF

41. CD14 dim CD16 + and CD14 + CD16 + Monocytes in Obesity and During Weight Loss

Author

Poitou, Christine, primary, Dalmas, Elise, additional, Renovato, Mariana, additional, Benhamo, Vanessa, additional, Hajduch, Froogh, additional, Abdennour, Meriem, additional, Kahn, Jean-François, additional, Veyrie, Nicolas, additional, Rizkalla, Salwa, additional, Fridman, Wolf-Hervé, additional, Sautès-Fridman, Catherine, additional, Clément, Karine, additional, and Cremer, Isabelle, additional

Published
2011
Full Text
View/download PDF

43. Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

Author

Tahara, Hideaki, primary, Sato, Marimo, additional, Thurin, Magdalena, additional, Wang, Ena, additional, Butterfield, Lisa H, additional, Disis, Mary L, additional, Fox, Bernard A, additional, Lee, Peter P, additional, Khleif, Samir N, additional, Wigginton, Jon M, additional, Ambs, Stefan, additional, Akutsu, Yasunori, additional, Chaussabel, Damien, additional, Doki, Yuichiro, additional, Eremin, Oleg, additional, Fridman, Wolf Hervé, additional, Hirohashi, Yoshihiko, additional, Imai, Kohzoh, additional, Jacobson, James, additional, Jinushi, Masahisa, additional, Kanamoto, Akira, additional, Kashani-Sabet, Mohammed, additional, Kato, Kazunori, additional, Kawakami, Yutaka, additional, Kirkwood, John M, additional, Kleen, Thomas O, additional, Lehmann, Paul V, additional, Liotta, Lance, additional, Lotze, Michael T, additional, Maio, Michele, additional, Malyguine, Anatoli, additional, Masucci, Giuseppe, additional, Matsubara, Hisahiro, additional, Mayrand-Chung, Shawmarie, additional, Nakamura, Kiminori, additional, Nishikawa, Hiroyoshi, additional, Palucka, A Karolina, additional, Petricoin, Emanuel F, additional, Pos, Zoltan, additional, Ribas, Antoni, additional, Rivoltini, Licia, additional, Sato, Noriyuki, additional, Shiku, Hiroshi, additional, Slingluff, Craig L, additional, Streicher, Howard, additional, Stroncek, David F, additional, Takeuchi, Hiroya, additional, Toyota, Minoru, additional, Wada, Hisashi, additional, Wu, Xifeng, additional, Wulfkuhle, Julia, additional, Yaguchi, Tomonori, additional, Zeskind, Benjamin, additional, Zhao, Yingdong, additional, Zocca, Mai-Britt, additional, and Marincola, Francesco M, additional

Published
2009
Full Text
View/download PDF

44. Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses

Author

Adotévi, Olivier, primary, Mollier, Karine, additional, Neuveut, Christine, additional, Cardinaud, Sylvain, additional, Boulanger, Emmanuelle, additional, Mignen, Blandine, additional, Fridman, Wolf-Hervé, additional, Zanetti, Maurizio, additional, Charneau, Pierre, additional, Tartour, Eric, additional, Lemonnier, François, additional, and Langlade-Demoyen, Pierre, additional

Published
2006
Full Text
View/download PDF

45. Trial Watch Dendritic cell-based interventions for cancer therapy.

Author

Vacchelli, Erika, Vitale, Ilio, Eggermont, Alexander, Fridman, Wolf Hervé, Fučíková, Jitka, Cremer, Isabelle, Galon, Jérôme, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, and Galluzzi, Lorenzo

Subjects
DENDRITIC cells, AUTOIMMUNE diseases, CANCER patients, CANCER treatment, PATHOLOGY
Abstract

Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental efort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge®) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial watch dealing with this exciting ield of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

46. Trial Watch: Immunostimulatory cytokines.

Author

Vacchelli, Erika, Eggermont, Alexander, Fridman, Wolf Hervé, Galon, Jérôme, Zitvogel, Laurence, Kroemer, Guido, and Galluzzi, Lorenzo

Subjects
CYTOKINES, IMMUNOLOGICAL adjuvants, CANCER patients, CARCINOGENESIS, CANCER invasiveness
Abstract

During the past two decades, the notion that cancer would merely constitute a cell-intrinsic disease has gradually been complemented by a model postulating that the immune system plays a relevant role during all stages of oncogenesis and tumor progression. Along with this conceptual shift, several strategies have been devised to stimulate tumorspeciic immune responses, including relatively unselective approaches such as the systemic administration of adjuvants or immunomodulatory cytokines. One year ago, in the July issue of OncoImmunology, we described the main biological features of this large group of proteins and discussed the progress of ongoing clinical studies evaluating their safety and therapeutic potential in cancer patients. Here, we summarize the latest developments in this area of clinical research, focusing on high impact studies that have been published during the last 13 mo and clinical trials launched in the same period to investigate which cytokines can be employed as safe and efficient immunostimulatory interventions against cancer. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

47. Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Author

Vacchelli, Erika, Eggermont, Alexander, Fridman, Wolf Hervé, Galon, Jérôme, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, and Galluzzi, Lorenzo

Subjects
THERAPEUTICS, IMMUNOTHERAPY, ANTINEOPLASTIC agents, MELANOMA, IMMUNOSUPPRESSION
Abstract

Adoptive cell transfer (ACT) represents a prominent form of immunotherapy against malignant diseases. ACT is conceptually distinct from dendritic cell-based approaches (which de facto constitute cellular vaccines) and allogeneic transplantation (which can be employed for the therapy of hematopoietic tumors) as it involves the isolation of autologous lymphocytes exhibiting antitumor activity, their expansion/activation ex vivo and their reintroduction into the patient. Re-infusion is most often performed in the context of lymphodepleting regimens (to minimize immunosuppression by host cells) and combined with immunostimulatory interventions, such as the administration of Toll-like receptor agonists. Autologous cells that are suitable for ACT protocols can be isolated from tumor-infiltrating lymphocytes or generated by engineering their circulating counterparts for the expression of transgenic tumor-specific T-cell receptors. Importantly, lymphocytes can be genetically modified prior to re-infusion for increasing their persistence in vivo, boosting antitumor responses and minimizing side effects. Moreover, recent data indicate that exhausted antitumor T lymphocytes may be rejuvenated in vitro by exposing them to specific cytokine cocktails, a strategy that might considerably improve the clinical success of ACT. Following up the Trial Watch that we published on this topic in the third issue of OncoImmunology (May 2012), here we summarize the latest developments in ACT-related research, covering both high-impact studies that have been published during the last 13 months and clinical trials that have been initiated in the same period to assess the antineoplastic profile of this form of cellular immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

48. Trial watch: Chemotherapy with immunogenic cell death inducers.

Author

Vacchelli, Erika, Senovilla, Laura, Eggermont, Alexander, Fridman, Wolf Hervé, Galon, Jérôme, Zitvogel, Laurence, Kroemer, Guido, and Galluzzi, Lorenzo

Subjects
CANCER chemotherapy, CELL death, DISEASE progression, IMMUNE response, CYCLOPHOSPHAMIDE, DOXORUBICIN, OXALIPLATIN, CLINICAL trials
Abstract

It is now clear that the immune system plays a critical role not only during oncogenesis and tumor progression, but also as established neoplastic lesions respond to therapy. Selected cytotoxic chemicals can indeed elicit immunogenic cell death, a functionally peculiar type of apoptosis that stimulates tumorspecific cognate immune responses. Such immunogenic chemotherapeutics include cyclophosphamide, doxorubicin and oxaliplatin (which are approved by FDA for the treatment of various hematological and solid malignancies), mitoxantrone (which is currently employed both as an anticancer agent and against multiple sclerosis) and patupilone (a microtubular poison in clinical development). One year ago, in the second issue of OncoImmunology, we discussed the scientific rationale behind immunogenic chemotherapy and reviewed the status of recent clinical trials investigating the off-label use of cyclophosphamide, doxorubicin, oxaliplatin and mitoxantrone in cancer patients. Here, we summarize the latest developments in this area of clinical research, covering both high-impact studies that have been published during the last 13 months and clinical trials that have been initiated in the same period to assess the antineoplastic profile of immunogenic chemotherapeutics. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

49. Trial watch Peptide vaccines in cancer therapy.

Author

Vacchelli, Erika, Martins, Isabelle, Alexander, Alexander, Fridman, Wolf Hervé, Galon, Jerome, Sautès-Fridman, Catherine, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, and Galluzzi, Lorenzo

Subjects
PEPTIDE drugs, CANCER treatment, VACCINATION, CANCER prevention
Abstract

Prophylactic vaccination constitutes one of the most prominent medical achievements of history. This concept was first demonstrated by the pioneer work of Edward Jenner, dating back to the late 1790s, after which an array of preparations that confer life-long protective immunity against several infectious agents has been developed. The ensuing implementation of nation-wide vaccination programs has de facto abated the incidence of dreadful diseases including rabies, typhoid, cholera and many others. Among all, the most impressive result of vaccination campaigns is surely represented by the eradication of natural smallpox infection, which was definitively certified by the WHO in 1980. The idea of employing vaccines as anticancer interventions was first theorized in the 1890s by Paul Ehrlich and William Coley. However, it soon became clear that while vaccination could be efficiently employed as a preventive measure against infectious agents, anticancer vaccines would have to (1) operate as therapeutic, rather than preventive, interventions (at least in the vast majority of settings), and (2) circumvent the fact that tumor cells often fail to elicit immune responses. During the past 30 y, along with the recognition that the immune system is not irresponsive to tumors (as it was initially thought) and that malignant cells express tumorassociated antigens whereby they can be discriminated from normal cells, considerable efforts have been dedicated to the development of anticancer vaccines. Some of these approaches, encompassing cell-based, DNA-based and purified component-based preparations, have already been shown to exert conspicuous anticancer effects in cohorts of patients affected by both hematological and solid malignancies. In this Trial Watch, we will summarize the results of recent clinical trials that have evaluated/are evaluating purified peptides or fulllength proteins as therapeutic interventions against cancer [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

50. Prognostic and predictive value of the immune infiltrate in cancer.

Author

Senovilla, Laura, Vacchelli, Erika, Galon, Jerome, Adjemian, Sandy, Eggermont, Alexander, Fridman, Wolf Hervé, Sautès-Fridman, Catherine, Yuting Ma, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, and Galluzzi, Lorenzo

Subjects
IMMUNOSUPPRESSION, TRANSFORMING growth factors, CANCER prognosis, CARCINOGENESIS, CANCER cells, LEUCOCYTES, CANCER invasiveness
Abstract

Solid tumors are constituted of a variety of cellular components, including bona fide malignant cells as well as endothelial, structural and immune cells. On one hand, the tumor stroma exerts major pro-tumorigenic and immunosuppressive functions, reflecting the capacity of cancer cells to shape the microenvironment to satisfy their own metabolic and immunological needs. On the other hand, there is a component of tumor-infiltrating leucocytes (TILs) that has been specifically recruited in the attempt to control tumor growth. Along with the recognition of the critical role played by the immune system in oncogenesis, tumor progression and response to therapy, increasing attention has been attracted by the potential prognostic and/or predictive role of the immune infiltrate in this setting. Data from large clinical studies demonstrate indeed that a robust infiltration of neoplastic lesions by specific immune cell populations, including (but not limited to) CD8+ cytotoxic T lymphocytes, Th1 and Th17 CD4+ T cells, natural killer cells, dendritic cells, and M1 macrophages constitutes an independent prognostic indicator in several types of cancer. Conversely, high levels of intratumoral CD4+CD25+FOXP3+ regulatory T cells, Th2 CD4+ T cells, myeloid-derived suppressor cells, M2 macrophages and neutrophils have frequently been associated with dismal prognosis. So far, only a few studies have addressed the true predictive potential of TILs in cancer patients, generally comforting the notion that-at least in some clinical settings- the immune infiltrate can reliably predict if a specific patient will respond to therapy or not. In this Trial Watch, we will summarize the results of clinical trials that have evaluated/are evaluating the prognostic and predictive value of the immune infiltrate in the context of solid malignancies. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results